-
AGM Voting Result FY21-222021-10-13 07:56:56Read More
-
AGM voting results FY20-212021-10-13 07:54:46Read More
-
AGM Voting results FY19-202021-10-13 07:52:00Read More
-
AGM Voting results FY18-192021-10-13 07:45:32Read More
-
AGM voting results FY17-182021-10-13 07:22:46Read More
-
AGM Voting Results FY16-172021-10-13 06:40:54Read More
-
AGM voting results FY15-162021-10-13 06:35:48Read More
-
AGM Voting results FY14-152021-10-13 06:30:09Read More
-
Notice of Board Meeting for Audited Financial Results and Dividend, if any11.05.2022Read More
-
Disclosure of material event – Update on Assignment of Trademark for Azmarda® indicated for heart failure patients with reduced ejection fraction (HfrEF) from Novartis AG, Switzerland for India13.04.2022Read More
-
Assignment of Trademark for Azmarda® from Novartis AG, Switzerland for India01.04.2022Read More
-
Disclosure of material event – Resignation of Director14.03.2022Read More
-
Intimation of record date for Interim Dividend14.02.2022Read More
-
Declaration of Interim Dividend for FY 2021-2214.02.2022Read More
-
Q3 FY22 Press Release14.02.2022Read More
-
Q3 FY22 Investor Presentation14.02.2022Read More
-
Q3 FY22 Results Sheet14.02.2022Read More
-
Schedule of Investors /Analysts’ call with Management on 15.02.2022 and Registration Log-in details.08.02.2022Read More
-
Investor presentation in relation to Acquisition of Brands and Related Assets from Sanzyme Private Limited – 27.01.202227.01.2022Read More
-
Disclosure of material event – Resignation of Director27.01.2022Read More
-
Press Release in relation to Acquisition of Brands and Related Assets from Sanzyme Private Limited27.01.2022Read More
-
Disclosure of material event – Acquisition of Brands and Related Assets from Sanzyme Private Limited27.01.2022Read More
-
Schedule of Investors / Analysts’ call with Management on 27.01.2022 and Registration Log-in details for the same26.01.2022Read More
-
Press Release regarding the launch of Molupiravir for the Indian market29.12.2021Read More
-
Q2 Results 2021-CNBC TV1815.11.2021Read More
-
Q2 FY22 Press Release11.11.2021Read More
-
Q2 FY22 Investor Presentation11.11.2021Read More
-
Q2 FY22 Results Sheet11.11.2021Read More
-
Grant of options under ESOS Scheme01.10.2021Read More
-
Change in Key Managerial Personnel01.10.2021Read More
-
Disclosure of Material events/ information – Submission of application to Stock Exchanges for reclassification17.09.2021Read More
-
AGM Recording15.09.2021Read More
-
Disclosure of material event/information – Re-classification of status from promoter to public of certain promoters/promoter group members10.09.2021Read More
-
Disclosure of material event/information – Appointment of Statutory Auditor10.09.2021Read More
-
Disclosure of material event/information – Proceedings of the Annual General Meeting10.09.2021Read More
-
Result of voting at Annual General Meeting10.09.2021Read More
-
Disclosure of material event/information – Resignation of Chief Financial Officer07.09.2021Read More
-
Presentation made to Investors – 12.08.202112.08.2021Read More
-
Unaudited Financial Results 31.12.202019.07.2021Read More
-
Intimation of Record Date19.07.2021Read More
-
Press Release for Unaudited Financial Results – 31.12.202019.07.2021Read More
-
Presentation made to Investors – 10.02.202119.07.2021Read More
-
Schedule of meeting with institutional investors19.07.2021Read More
-
Presentation made to Investors – 02.03.202119.07.2021Read More
-
Outcome of Board meeting19.07.2021Read More
-
Institution of new Employee Stock Option Scheme19.07.2021Read More
-
Launch of new dedicated division “RENOVA” to enter Nephrology segment in India19.07.2021Read More
-
Disclosure of receipt of requests from the promoters/ promoter group members seeking re-classification of status as public19.07.2021Read More
-
Notice of Board Meeting19.07.2021Read More
-
Recommendation of final dividend19.07.2021Read More
-
Schedule of Investors/ Analysts’ call with management on 15.06.2021 and Registration/Log-in details for the same19.07.2021Read More
-
Audited Financial Results 31.03.202119.07.2021Read More
-
Press Release for Audited Financial Results – 31.03.202119.07.2021Read More
-
Q4 FY21 Earnings Call Transcript19.07.2021Read More
-
Instructions19.07.2021Read More
-
Postal Ballot Form19.07.2021Read More
-
Disclosure of material event/information – 02.07.202119.07.2021Read More
-
Newspaper advertisement for Postal Ballot19.07.2021Read More
-
FY 2019 – 202015.07.2021Read More
-
FY 2019 – 202015.07.2021Read More
-
Q1 FY22 Earnings Call Audio30.06.2021Read More
-
Postal Ballot Notice – 25.06.202125.06.2021Read More
-
Recommendation of Final Dividend for FY 2020-2114.06.2021Read More
-
Views of Board of Directors on the Reclassification Request08.06.2021Read More
-
Newspaper cutting of extract of Consolidated Financial Results 31.03.202131.03.2021Read More
-
Registration/ Log-in details for virtual call with management on 02.03.202102.03.2021Read More
-
Declaration of Interim Dividend10.02.2021Read More
-
Board to consider and declare interim dividend for FY 2020-2105.02.2021Read More